Endocrinology Department, Hospital de Santa Maria, Centro Hospitalar Universitário de Lisboa Norte, Lisbon, Portugal.
Centre for Endocrinology, William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK; Servicio de Endocrinología, Hospital General de Zona Número 8, Instituto Mexicano del Seguro Social, Ciudad de México, México.
Growth Horm IGF Res. 2022 Jun;64:101467. doi: 10.1016/j.ghir.2022.101467. Epub 2022 May 17.
The most frequent diagnosis underlying the finding of an elevated growth hormone (GH) and insulin-like growth factor-1 (IGF-1) is acromegaly due to a GH-secreting pituitary tumour. However, GH and IGF-1 levels can be discordant in patients with acromegaly due to early or partially treated disease, or there might be another cause of high GH or high IGF-1 unrelated to acromegaly, such as pre-analytical and technical pitfalls, physiological circumstances and pathological conditions. High GH and normal or low serum IGF-1, or alternatively, normal GH with elevated serum IGF-1, should be carefully assessed to avoid misinterpreting the activity of acromegaly or misdiagnosing a patient with acromegaly. We summarise here these biochemical discrepancies in the evaluation of the somatotroph axis.
导致生长激素 (GH) 和胰岛素样生长因子-1 (IGF-1) 升高的最常见诊断是由于生长激素分泌性垂体肿瘤引起的肢端肥大症。然而，由于疾病早期或部分治疗，或可能存在与肢端肥大症无关的其他导致 GH 或 IGF-1 升高的原因，如分析前和技术缺陷、生理情况和病理情况，肢端肥大症患者的 GH 和 IGF-1 水平可能不一致。应仔细评估高 GH 和正常或低血清 IGF-1，或相反，正常 GH 和高血清 IGF-1，以避免错误解读肢端肥大症的活动或误诊肢端肥大症患者。我们在此总结了评估生长激素轴时这些生化差异。
